1. Managing Anemia in Lower-Risk MDS

3. Introduction

4. IPSS Risk Score: De Novo MDS International MDS Risk Analysis Workshop, 1997

5. IPSS-R: Prognostic Risk Groups/Scores*

6. MDS Risk Groups Defined by Clinical and Molecular Prognostic Models

7. Management of Lower-Risk MDS

8. Management Algorithm in Lower-Risk MDS

9. Predictive Model for Response to rEPO + GCSF Nordic MDS Group (N = 98)

10. Mean Non-Transfused Hemoglobin by Treatment Cycle

11. Duration of Transfusion-Independence in Isolated Del(5q) vs Int/Complex

12. Azacitidine Dose and Schedule in Lower-Risk MDS Frequency of Major HI in Evaluable Patients (N = 139)

13. Emerging Therapies and Targets

14. Agents in Development for Anemia in Lower-Risk MDS

15. Luspatercept (ACE-536)

16. MEDALIST Trial: Study Design

17. MEDALIST Trial: RBC-TI ≥ 8 Weeks (Primary Endpoint)

18. MEDALIST Trial: TEAEs ≥ 10% in Either Arm

19. MEDALIST Trial: RBC-TI ≥ 12 Weeks (Secondary Endpoint)

20. MEDALIST Trial: Duration of RBC-TI Response in Primary Endpoint Responders

21. Eltrombopag

22. Eltrombopag: Hematological Response at the Primary Endpoint

23. Eltrombopag: AEs

24. SintraRev: Study Design

25. SintraRev: Efficacy Results at Week 12

26. SintraRev: Efficacy Results During All Study (Median Follow-Up: 24 Months)

27. IMerge: Imtelstat Most Common TEAEs

28. IMerge: Results

29. Tomaralimab Monotherapy in Low- or Intermediate 1-risk MDS After Failing Prior HMA Therapy

30. TELESTO: Study Design

31. TELESTO: EFS (Primary Endpoint)

32. TELESTO: OS, Serum Ferritin

33. TELESTO: Exposure-Adjusted AEs

34. Patient Selection for Emerging Therapies

35. The Potential Clinical Impact of Novel Therapies

36. Conclusions

37. Abbreviations

38. Abbreviations (cont)

39. Abbreviations (cont)

40. Abbreviations (cont)